

February 19, 2026

Hikal Limited: Change in limits for Bank facilities

Summary of rating action

| Instrument* | Previous Rated Amount (Rs. crore) | Current Rated Amount (Rs. crore) | Rating Action |
|---|-----------------------------------|----------------------------------|--|
| Long-term fund-based term loans | 323.96 | 323.96 | [ICRA]A (Stable); Outstanding |
| Long-term – fund-based – working capital facilities | 254.00 | 384.00 | [ICRA]A (Stable); Outstanding |
| Long-term – unallocated limits (\$ million)# | 6.27 | - | - |
| Short-term – fund-based facilities | 280.50 | 190.50 | [ICRA]A2+; Outstanding |
| Short-term – non-fund based facilities | 40.00 | 62.00 | [ICRA]A2+; Outstanding |
| Short-term – unallocated facilities | 195.74 | - | - |
| Unallocated facilities# | - | 133.74+ \$6.27 million | [ICRA]A (Stable)/ [ICRA]A2+; Outstanding |
| Total | 1,094.20+ \$6.27 million | 1,094.20+ \$6.27 million | |

*Instrument details are provided in Annexure-I

#Though a part of the long-term loans of Hikal are denominated in foreign currency, ICRA's ratings for the same are on national rating scale, as distinct from an international rating scale

Rationale

This rationale is being released to convey the change in the rated limits as depicted in the table above, based on the latest information received from the entity.

Please refer to the following link for the previous detailed rationale that captures the key rating drivers and their description, the liquidity position, environmental and social risks and rating sensitivities : [click here](#)

Analytical approach

| Analytical Approach | Comments |
|---------------------------------|--|
| Applicable rating methodologies | Corporate Credit Rating Methodology Pharmaceuticals Agrochemicals |
| Parent/Group support | Not Applicable |
| Consolidation/Standalone | For arriving at the ratings, ICRA has considered the consolidated financials of Hikal Limited. Refer to the Annexure-II for the list of entities considered for consolidation. |

About the company

Hikal was incorporated on July 8, 1988, as a private limited company, Hikal Chemicals Industries Private Limited, by the Hiremath family and Surajmukhi Investments & Finance Limited, a wholly owned subsidiary of Kalyani Steels Limited. The company was listed in 1995; and subsequently was renamed as Hikal Limited in 2000.

The company has a commercial production facility at Mahad (Maharashtra) for intermediates used in dyes, pharmaceuticals and agrochemicals. The plant at Taloja (Maharashtra), which manufactures crop protection chemicals, is the only fully integrated plant in the world to produce Thiabendazole. The facility at Panoli (Gujarat) produces key intermediates and regulatory starting materials for the pharmaceutical industry and is certified by the US FDA, PMDA (Japan) and EUGMP. The Bangalore facility manufactures key APIs for the pharmaceutical industry and has been approved by the US FDA, PMDA (Japan) and EU Authorities. The company has an R&D centre in Pune (Maharashtra), which provides end-to-end services for APIs, custom synthesis, analytical development and scale-up from development to commercial manufacturing.

Key financial indicators (audited)

| Hikal – Consolidated | FY2024 | FY2025 | H1 FY2026* |
|--|--------|---------|------------|
| Operating income | 1784.6 | 1,859.8 | 698.9 |
| PAT | 69.6 | 87.8 | -57.3 |
| OPBDIT/OI | 15.0% | 17.5% | 4.6% |
| PAT/OI | 3.9% | 4.7% | -8.2% |
| Total outside liabilities/Tangible net worth (times) | 1.1 | 1.0 | 1.0 |
| Total debt/OPBDIT (times) | 3.1 | 2.4 | 10.6 |
| Interest coverage (times) | 4.7 | 4.3 | 1.0 |

Source: Company, ICRA Research; * Provisional numbers; All ratios as per ICRA's calculations; Amount in Rs. crore; PAT: Profit after tax; OPBDIT: Operating profit before depreciation, interest, taxes and amortisation

Status of non-cooperation with previous CRA: Not applicable

Any other information: None

Rating history for past three years

| Current rating (FY2026) | | | | Chronology of rating history for the past 3 years | | | | | | | |
|-------------------------|-----------|-------------------------|------------------|---|-------------------|--------|--------|--------------|-------------------|--------------|-------------------|
| | | | | FY2026 | | FY2025 | | FY2024 | | FY2023 | |
| Instrument | Type | Amount rated (Rs crore) | Feb 19, 2026 | Date | Rating | Date | Rating | Date | Rating | Date | Rating |
| Fund Based limits | Long Term | 384.00 | [ICRA]A (Stable) | Apr 09, 2025 | [ICRA]A+ (Stable) | - | - | Apr 03, 2023 | [ICRA]A+ (Stable) | Jun 20, 2022 | [ICRA]A+ @ |
| | | | | Aug 19, 2025 | [ICRA]A+ (Stable) | - | - | Mar 04, 2024 | [ICRA]A+ (Stable) | Mar 14, 2023 | [ICRA]A+ (Stable) |
| | | | | Nov 24, 2025 | [ICRA]A (Stable) | - | - | - | - | - | - |
| Fund Based-Term Loan | Long Term | 323.96 | [ICRA]A (Stable) | Apr 09, 2025 | [ICRA]A+ (Stable) | - | - | Apr 03, 2023 | [ICRA]A+ (Stable) | Jun 20, 2022 | [ICRA]A+ @ |
| | | | | Aug 19, 2025 | [ICRA]A+ (Stable) | - | - | Mar 04, 2024 | [ICRA]A+ (Stable) | Mar 14, 2023 | [ICRA]A+ (Stable) |
| | | | | Nov 24, 2025 | [ICRA]A (Stable) | - | - | - | - | - | - |
| Unallocated limits | Long Term | - | - | Apr 09, 2025 | [ICRA]A+ (Stable) | - | - | Apr 03, 2023 | [ICRA]A+ (Stable) | Jun 20, 2022 | [ICRA]A+ @ |
| | | | | Aug 19, 2025 | [ICRA]A+ (Stable) | - | - | Mar 04, 2024 | [ICRA]A+ (Stable) | Mar 14, 2023 | [ICRA]A+ (Stable) |
| | | | | Nov 24, 2025 | [ICRA]A (Stable) | - | - | - | - | - | - |

| | | | | | | | | | | | |
|------------------------------|-----------------------|------------------------|-----------------------------|--------------|------------|---|---|--------------|-------------------|--------------|-------------------|
| Fund Based limits | Short Term | 190.50 | [ICRA]A2+ | Apr 09, 2025 | [ICRA]A1 | - | - | Apr 03, 2023 | [ICRA]A1 | Jun 20, 2022 | [ICRA]A1 @ |
| | | | | Aug 19, 2025 | [ICRA]A1 | - | - | Mar 04, 2024 | [ICRA]A1 | Mar 14, 2023 | [ICRA]A1 |
| | | | | Nov 24, 2025 | [ICRA]A2 + | - | - | - | - | - | - |
| Non Fund Based limits | Short Term | 62.00 | [ICRA]A2+ | Apr 09, 2025 | [ICRA]A1 | - | - | Apr 03, 2023 | [ICRA]A1 | Jun 20, 2022 | [ICRA]A1 @ |
| | | | | Aug 19, 2025 | [ICRA]A1 | - | - | Mar 04, 2024 | [ICRA]A1 | Mar 14, 2023 | [ICRA]A1 |
| | | | | Nov 24, 2025 | [ICRA]A2 + | - | - | - | - | - | - |
| Unallocated limits | Short Term | - | - | Apr 09, 2025 | [ICRA]A1 | - | - | Apr 03, 2023 | [ICRA]A1 | Mar 14, 2023 | [ICRA]A1 |
| | | | | Aug 19, 2025 | [ICRA]A1 | - | - | Mar 04, 2024 | [ICRA]A1 | - | - |
| | | | | Nov 24, 2025 | [ICRA]A2 + | - | - | - | - | - | - |
| Unallocated limits | Long Term/ Short Term | 133.74+ \$6.27 million | [ICRA]A (Stable)/ [ICRA]A2+ | - | - | - | - | - | - | - | - |
| Fund Based limits | Long Term | - | - | - | - | - | - | Apr 03, 2023 | [ICRA]A+ (Stable) | Mar 14, 2023 | [ICRA]A+ (Stable) |
| | | | | - | - | - | - | Mar 04, 2024 | [ICRA]A+ (Stable) | - | - |

@: Rating watch with Negative Implications

Complexity level of the rated instruments

| Instrument | Complexity Indicator |
|--|----------------------|
| Long-term term loan | Simple |
| Long-term fund-based – Working capital | Simple |
| Short-term fund-based | Simple |
| Short-term non-fund based | Simple |
| Long-term/Short-term – Unallocated | Not Applicable |

The Complexity Indicator refers to the ease with which the returns associated with the rated instrument could be estimated. It does not indicate the risk related to the timely payments on the instrument, which is rather indicated by the instrument's credit rating. It also does not indicate the complexity associated with analysing an entity's financial, business, industry risks or complexity related to the structural, transactional or legal aspects. Details on the complexity levels of the instruments are available on ICRA's website: [Click Here](#)

Annexure I: Instrument details

| ISIN | Instrument Name | Date of Issuance | Coupon Rate | Maturity | Amount Rated (Rs. crore) | Current Rating and Outlook |
|------|----------------------------|------------------|-------------|-----------|--------------------------|-----------------------------|
| NA | Term loan-I | FY2019 | NA | Feb 2027 | 26.20 | [ICRA]A (Stable) |
| NA | Term loan-II | FY2019 | NA | Sep 2026 | 21.10 | [ICRA]A (Stable) |
| NA | Term loan-III | FY2021 | NA | June 2028 | 185.00 | [ICRA]A (Stable) |
| NA | Term loan-IV | FY2023 | NA | June 2030 | 91.66 | [ICRA]A (Stable) |
| NA | Working capital Facilities | NA | NA | NA | 384.00 | [ICRA]A (Stable) |
| NA | Fund-based facilities | NA | NA | NA | 190.50 | [ICRA]A2+ |
| NA | Non-fund-based facility | NA | NA | NA | 62.00 | [ICRA]A2+ |
| NA | Unallocated | NA | NA | NA | 133.74+ \$6.27 million | [ICRA]A (Stable)/ [ICRA]A2+ |

Source: Company

[Please click here to view details of lender-wise facilities rated by ICRA](#)

Annexure II: List of entities considered for consolidated analysis

| Company Name | Hikal Ownership | Consolidation Approach |
|-------------------------|-----------------|------------------------|
| Acoris Research Limited | 100.00% | Full Consolidation |
| Hikal LLC, USA | 100.00% | Full Consolidation |

Source: Annual report, FY2025

ANALYST CONTACTS

Jitin Makkar

+91 124 4545 368

jitinm@icraindia.com

Kinjal Shah

+91 22 6114 3400

kinjal.shah@icraindia.com

Deepak Jotwani

+91 12 4454 5870

deepak.jotwani@icraindia.com

Gaurav Kushwaha

+91 40 4547 4829

gaurav.kushwaha@icraindia.com

RELATIONSHIP CONTACT

L. Shivakumar

+91 22 6114 3406

shivakumar@icraindia.com

MEDIA AND PUBLIC RELATIONS CONTACT

Ms. Naznin Prodhani

Tel: +91 124 4545 860

communications@icraindia.com

HELPLINE FOR BUSINESS QUERIES

+91-9354738909 (open Monday to Friday, from 9:30 am to 6 pm)

info@icraindia.com

ABOUT ICRA LIMITED

ICRA Limited was set up in 1991 by leading financial/investment institutions, commercial banks and financial services companies as an independent and professional investment Information and Credit Rating Agency.

Today, ICRA and its subsidiaries together form the ICRA Group of Companies (Group ICRA). ICRA is a Public Limited Company, with its shares listed on the Bombay Stock Exchange and the National Stock Exchange. The international Credit Rating Agency Moody's Investors Service is ICRA's largest shareholder.

For more information, visit www.icra.in

ICRA Limited



Registered Office

B-710, Statesman House, 148 Barakhamba Road, New Delhi-110001

Tel: +91 11 23357940-45



Branches



© Copyright, 2026 ICRA Limited. All Rights Reserved.

Contents may be used freely with due acknowledgement to ICRA.

ICRA ratings should not be treated as recommendation to buy, sell or hold the rated debt instruments. ICRA ratings are subject to a process of surveillance, which may lead to revision in ratings. An ICRA rating is a symbolic indicator of ICRA's current opinion on the relative capability of the issuer concerned to timely service debts and obligations, with reference to the instrument rated. Please visit our website www.icra.in or contact any ICRA office for the latest information on ICRA ratings outstanding. All information contained herein has been obtained by ICRA from sources believed by it to be accurate and reliable, including the rated issuer. ICRA however has not conducted any audit of the rated issuer or of the information provided by it. While reasonable care has been taken to ensure that the information herein is true, such information is provided 'as is' without any warranty of any kind, and ICRA in particular, makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. Also, ICRA or any of its group companies may have provided services other than rating to the issuer rated. All information contained herein must be construed solely as statements of opinion, and ICRA shall not be liable for any losses incurred by users from any use of this publication or its contents..